<DOC>
	<DOCNO>NCT01478373</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Dovitinib patient gastrointestinal stromal tumor refractory and/or intolerant Imatinib</brief_summary>
	<brief_title>Efficacy Safety Dovitinib Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant Imatinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histologically confirm GIST anatomical location , 1 ) unresectable and/ metastatic document disease progression therapy imatinib 2 ) surgically remove localized GIST , recurrent adjuvant imatinib recurrent within first 3 month discontinuation adjuvant imatinib 3 ) patient unresectable and/or metastatic GIST intolerant imatinib Positive immunohistochemical stain cKIT ( CD117 ) ; negative stain KIT , either positive stain DOG1 identified mutation KIT PDGFRA gene Documented disease progression accord RECIST ( version 1.1 ) prior therapy imatinib dose least 400mg/day patient unresectable and/or metastatic GIST intolerant imatinib At least one measurable GIST lesion accord RECIST ( version 1.1 ) . Adequate bone marrow , liver renal function Patients receive tyrosinekinase inhibitor imatinib GIST Patients receive cytotoxic drug ≤ 4 week prior start Dovitinib ( TKI258 ) Patients treat plan treat concomitantly cytotoxic antineoplastic treatment , chemotherapy , immunotherapy , biological response modifier , radiotherapy Patients another primary malignancy within 3 year prior start study drug Patients undergone major surgery ( e.g . intrathoracic , intraabdominal intrapelvic ) ≤ 4 week prior start Dovitinib ( TKI258 ) recover adverse effect therapy Patients history pulmonary embolism ( PE ) , untreated deep venous thrombosis ( DVT ) within past 6 month Patients impaired cardiac function clinically significant cardiac disease Patients impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption Dovitinib Patients prior complete gastrectomy Patients brain metastasis history brain metastasis Patients currently receive anticoagulation treatment therapeutic dos warfarin equivalent anticoagulant Pregnant breastfeeding woman Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>GIST</keyword>
	<keyword>Dovitinib</keyword>
</DOC>